Home » About Us » Team


Acelot is a private company that began drug discovery work in 2011 using technology developed at the University of California at Santa Barbara that has been validated through multiple peer-reviewed publications. Headquartered in Santa Barbara, the company has received numerous prestigious SBIR grants from the National Institutes of Health and the National Science Foundation.

Executive Team

Professor Ambuj K. Singh (President and CEO)
The founder of Acelot, Prof. Singh, has authored over 140 scientific papers in the areas of bioinformatics, data mining, databases, and graph algorithms. He holds a Ph.D. from the University of Texas at Austin and a Bachelor's degree from the Indian Institute of Technology. He is currently a professor in the departments of Computer Science and Biomolecular Science & Engineering at the University of California, Santa Barbara. He works on developing the basic data and graph analysis methods that form the core IP of the company.
Christian A. Lang, Ph.D. (Chief Technology Officer)
Dr. Lang has extensive industry experience in research and productization of data mining and data management algorithms. He has successfully lead teams of researchers and software engineers, resulting in the development and delivery of innovative new features to well-known information management products such as IBM's flagship database DB2. He has published numerous peer reviewed papers in leading database and data mining conferences and journals and holds or has applied for more than 15 U.S. patents. Dr. Lang holds a Ph.D. degree (2003) in computer science from the University of California, Santa Barbara.

Scientific Advisors

Gilbert M. Rishton, Ph.D. (Scientific Advisor)
Dr. Rishton is the Founder and Director of the Alzheimer's Institute at CSUCI. He has led drug discovery programs in pharma for over 15 years. During his years at Amgen, he was the founding medicinal chemist at the Thousand Oaks site. Dr. Rishton was responsible for much of the program initiation and group building for the Amgen Small Molecule Drug Discovery Group, which has grown to become one of the most formidable in the pharmaceutical industry. He has managed drug discovery programs in inflammation, oncology, and central nervous system disease.
Stuart C. Feinstein, Ph.D. (Scientific Advisor)
Dr. Feinstein is Co-Director of the Neuroscience Research Institute and a professor in the Department of Molecular, Cellular and Developmental Biology at the University of California, Santa Barbara. His primary area of research focuses upon the molecular basis of neurodegenerative diseases, with an emphasis upon Alzheimer’s and related dementias. Dr. Feinstein earned his undergraduate degree in biochemistry at the University of California, Berkeley and his Ph.D. in biochemistry and biophysics at the University of California School of Medicine in San Francisco. Subsequently, he was a postdoctoral fellow in neurobiology at the Stanford University School of Medicine. He joined the UCSB faculty in 1986.

Board of Directors

Robin Campbell, Ph.D. (Board Director)
Robin’s professional career spans more than 25 years and includes both U.S. and international experience in pharmaceutical and biotechnology sales, marketing, product development and general management. From 2004 to 2008, Robin was President and CEO of Naryx Pharma, a venture-backed specialty pharmaceutical company developing novel, topically delivered treatments for chronic sinusitis and other conditions treatable by intranasal drug delivery. Prior to joining Naryx Pharma, Robin was at Amgen Inc., where his last position was Vice President and General Manager of the Oncology Business Unit. In this role, Robin led an integrated team responsible for the marketing, sales and medical development of products generating over $1 billion in revenue.